- Home
- AMGN vs BLK Comparison
AMGN vs BLK Comparison
Compare AMGN & BLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- BLK
- Stock Information
- Founded
- AMGN 1980
- BLK 1988
- Country
- AMGN United States
- BLK United States
- Employees
- AMGN N/A
- BLK N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- BLK Investment Bankers/Brokers/Service
- Sector
- AMGN Health Care
- BLK Finance
- Exchange
- AMGN Nasdaq
- BLK Nasdaq
- Market Cap
- AMGN 147.3B
- BLK 157.4B
- IPO Year
- AMGN N/A
- BLK 1999
- Fundamental
- Price
- AMGN $263.38
- BLK $1,029.50
- Analyst Decision
- AMGN Buy
- BLK Strong Buy
- Analyst Count
- AMGN 22
- BLK 12
- Target Price
- AMGN $329.05
- BLK $1,040.50
- AVG Volume (30 Days)
- AMGN 4.7M
- BLK 790.6K
- Earning Date
- AMGN 02-04-2025
- BLK 01-10-2025
- Dividend Yield
- AMGN 3.62%
- BLK 1.98%
- EPS Growth
- AMGN N/A
- BLK 13.64
- EPS
- AMGN 7.83
- BLK 40.52
- Revenue
- AMGN $32,534,000,000.00
- BLK $19,361,000,000.00
- Revenue This Year
- AMGN $20.04
- BLK $14.18
- Revenue Next Year
- AMGN $3.41
- BLK $16.12
- P/E Ratio
- AMGN $33.62
- BLK $25.39
- Revenue Growth
- AMGN 21.25
- BLK 10.22
- 52 Week Low
- AMGN $253.30
- BLK $745.55
- 52 Week High
- AMGN $346.85
- BLK $1,082.45
- Technical
- Relative Strength Index (RSI)
- AMGN 31.29
- BLK 48.25
- Support Level
- AMGN $253.30
- BLK $1,051.22
- Resistance Level
- AMGN $280.00
- BLK $1,061.00
- Average True Range (ATR)
- AMGN 5.95
- BLK 22.96
- MACD
- AMGN -0.21
- BLK -4.61
- Stochastic Oscillator
- AMGN 35.90
- BLK 34.20
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About BLK BlackRock Inc.
BlackRock is the largest asset manager in the world, with $11.475 trillion in assets under management at the end of September 2024. Its product mix is fairly diverse, with 55% of managed assets in equity strategies, 26% in fixed income, 9% in multi-asset classes, 7% in money market funds, and 3% in alternatives. Passive strategies account for around two thirds of long-term AUM, with the company's ETF platform maintaining a leading market share domestically and on a global basis. Product distribution is weighted more toward institutional clients, which by our calculations account for around 80% of AUM. BlackRock is geographically diverse, with clients in more than 100 countries and more than one third of managed assets coming from investors domiciled outside the US and Canada.